Significant accounting policies Significant Accounting Policies [Text Block] Range [Domain] Statistical Measurement [Domain] Barinthus Biotherapeutics plc Barinthus Biotherapeutics plc [Member] Barinthus Biotherapeutics plc Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional Paid-In Capital Additional Paid-in Capital [Member] AB-101-001 Phase 1a/1b clinical trial expense AB-101-001 Phase 1a/b clinical trial expense AB-101-001 Phase 1a/b clinical trial expense Tabular List, Table Tabular List [Table Text Block] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Interest income Interest Income, Interest-Earning Asset Type of Restructuring [Domain] Type of Restructuring [Domain] Revenue from collaborations and licenses License [Member] Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (in USD per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities Liabilities, Fair Value Disclosure [Abstract] US treasury bills US Treasury Bill Securities [Member] Summary of collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Restructuring And Workforce Reduction Restructuring And Workforce Reduction [Member] Restructuring And Workforce Reduction Debt Securities, Unrealized Gain (Loss) Debt Securities, Unrealized Gain (Loss) Effective annual interest rate on royalty liability Effective Annual Interest Rate Of Royalty Liability Effective Annual Interest Rate Of Royalty Liability Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Issuance of common shares upon vesting of RSUs Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common shares pursuant to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Short Term Marketable Securities Investments in marketable securities, current [Member] Investments in marketable securities, current Adjustment to Compensation, Amount Adjustment to Compensation Amount Principles of consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Employee Stock Option Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Income taxes paid Income Taxes Paid Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Current assets: Assets, Current [Abstract] Total liabilities and stockholders’ equity Liabilities and Equity Recurring Fair Value, Recurring [Member] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Cover [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] General and administrative General and Administrative Expense [Member] Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Accounting Policies [Abstract] Revenue Recognition and Deferred Revenue [Abstract] One-Time Upfront Cash Payment One-Time Upfront Cash Payment [Member] One-Time Upfront Cash Payment Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Royalty interest sold, annual revenue threshold of highest tier Annual Revenue Threshold Annual Revenue Threshold Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc [Member] Alnylam Pharmaceuticals, Inc Entity Shell Company Entity Shell Company Research and development accruals Accrued Research And Development Research and development accruals Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Change in deferred license revenue Increase (Decrease) in Deferred Revenue Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Liability related to sale of future royalties Net liability related to sale of future royalties - beginning balance Net liability related to sale of future royalties - ending balance Liability Related To Sale Of Future Royalties, Noncurrent Liability Related To Sale Of Future Royalties, Noncurrent Name Measure Name Schedule of stock based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Lease liability, current Operating Lease, Liability, Current Document Fiscal Period Focus Document Fiscal Period Focus Contingencies and Commitments [Table] Contingencies and Commitments [Table] Award Timing Method Award Timing Method [Text Block] Award Type Award Type [Axis] Long-term debt Long-Term Debt Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Trading Symbol Trading Symbol Number of royalty entitlements Royalty Entitlements Royalty Entitlements Non-cash royalty revenue Non-Cash Royalty [Member] Non-Cash Royalty Non-cash royalty revenue Liability From Sale Of Future Royalties, Non Cash Royalty Income Liability From Sale Of Future Royalties, Non Cash Royalty Income Sub-licensing revenue percentage Sub-licensing revenue Percentage Sub-licensing revenue Percentage Entity Address, City or Town Entity Address, City or Town OPERATING ACTIVITIES Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Moderna Moderna [Member] Moderna Marketable Securities [Line Items] Marketable Securities [Line Items] Adjustments and reconciling items Segment Reporting, Other Segment Item, Amount Effect of foreign exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Assets Assets, Fair Value Disclosure [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Restructuring liabilities Restructuring Reserve, Current Reportable Segment Reportable Segment [Member] Reportable Segment Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Payroll accruals Accrued Payroll Current Accrued Payroll Current Equity investment Equity Method Investments Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] Common shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Marketable securities Marketable Securities [Table Text Block] Plan Name [Axis] Plan Name [Axis] PEO PEO [Member] Disposition of investments in marketable securities Proceeds from Sale, Maturity and Collection of Investments Interest income Investment Income, Interest Future royalty payments Royalty Payable Represents the royalty payable. Net change in operating items: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Stock Options Exercised Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income tax benefit Income Tax Expense (Benefit) Investments in marketable securities, current Investments, Fair Value Disclosure Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other segment expense Other segment expense Other segment expense Vaccitech Barinthus [Member] Barinthus Product and Service [Domain] Product and Service [Domain] Debt Securities, Available-for-Sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of changes in fair value of contingent consideration Business Combination, Contingent Consideration [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total Liabilities, Fair Value Disclosure Organization, Consolidation and Presentation of Financial Statements [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Issuance of common shares pursuant to exercise of stock options Proceeds from Stock Options Exercised City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Proceeds from collaborators Proceeds from Collaborators All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Noninterest Income, Other Operating Income Noninterest Income, Other Operating Income Commitments and Contingencies Disclosure [Abstract] INVESTING ACTIVITIES Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Equity Method Investments and Joint Ventures [Abstract] Realized gains or losses Debt Securities, Realized Gain (Loss) Subsequent Event Subsequent Event [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Money market funds Money Market Funds [Member] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Equity Components [Axis] Equity Components [Axis] Nature of business and future operations Nature of Operations [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash Investments and Cash Number of reportable segments Number of Reportable Segments Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Entity Address, State or Province Entity Address, State or Province Fair value measurements Fair Value Measurement, Policy [Policy Text Block] ONPATTRO ONPATTRO, global net sales [Member] ONPATTRO, global net sales Related and Nonrelated Parties [Domain] Related and Nonrelated Parties [Domain] Total current liabilities Liabilities, Current Collaborations and licenses Collaboration And Contracts [Member] Collaboration And Contracts [Member] Individual: Individual [Axis] Development and regulatory milestones payment per royalty, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty License Agreement Maximum Development And Regulatory Royalty Payment per Royalty Research and development Research and Development Expense [Member] Entity [Domain] Entity [Domain] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Percent of Costs related to Collaboration Percent of Costs related to Collaboration Percent of Costs related to Collaboration Severance And Employee Benefit Costs and Lease Expenses Severance And Employee Benefit Costs and Lease Expenses [Member] Severance And Employee Benefit Costs and Lease Expenses Document Fiscal Year Focus Document Fiscal Year Focus Basis of presentation Basis of Accounting, Policy [Policy Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Noncontrolling interest, ownership percentage by noncontrolling owners Subsidiary, Ownership Percentage, Noncontrolling Owner Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] Issuance of common shares pursuant to exercise of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Revenue from collaborations and licenses and Deferred Revenue Revenue from Contract with Customer [Policy Text Block] US government bonds US Government Bonds [Member] US Government Bonds [Member] Segment Reporting Disclosure Segment Reporting Disclosure [Text Block] US Government Securities, at Carrying Value US Government Securities, at Carrying Value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Ownership [Domain] Ownership [Domain] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Depreciation Depreciation, Depletion and Amortization Other non-current assets Other Assets, Noncurrent Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Revenues Revenues Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount OMERS OMERS [Member] OMERS Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Contingent consideration Fair value of contingent consideration Liability at beginning of the period Liability at end of the period Business Combination, Contingent Consideration, Liability, Noncurrent Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share price (in USD per share) Share Price Subsequent Event Type [Axis] Subsequent Event Type [Axis] Assets Assets [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Sale of future royalties Liabilities Related To Sale Of Future Royalties [Text Block] Liabilities Related To Sale Of Future Royalties Fair value measurements Fair Value Disclosures [Text Block] Stockholders’ equity Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Premium on closing stock price (as a percent) Premium on Closing Stock Price Premium on Closing Stock Price Research and development Research and Development Expense Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Arbutus Inc. Arbutus Inc. [Member] Arbutus Inc. [Member] Investment, Name [Axis] Investment, Name [Axis] Lease liability, non-current Operating Lease, Liability, Noncurrent Change in fair value of contingent consideration Increase (Decrease) In Fair Value Of Contingent Consideration Liability Increase (Decrease) In Fair Value Of Contingent Consideration Liability Ownership [Axis] Ownership [Axis] Loss on impairment of leasehold improvements and lab equipment Restructuring, Settlement and Impairment Provisions Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Anti-dilutive common shares excluded from calculation of loss per common share (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Bona fide collaboration Percentage Bona fide collaboration Percentage Bona fide collaboration Percentage Purchase of investments in marketable securities Payments to Acquire Investments Document Quarterly Report Document Quarterly Report Total Assets, Fair Value Disclosure Debt securities, available-for-sale, unrealized loss Position, number of positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Genevant Sciences Corporation Genevant Genevant Sciences Corporation [Member] Genevant Sciences Corporation [Member] Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Accrued investment income receivable Accrued Investment Income Receivable Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Consolidated net loss Reconciliation of Operating Profit (Loss) from Segments to Consolidated Imdusiran IM-PROVE I, II & III clinical trials expense Imdusiran IM-PROVE I, II & III Clinical Trials Expense Imdusiran IM-PROVE I, II & III Clinical Trials Expense Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Non-PEO NEO Non-PEO NEO [Member] Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Gross Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name All Award Types Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Increase (Decrease) in Accounts and Other Receivables Increase (Decrease) in Accounts and Other Receivables Compensation Amount Outstanding Recovery Compensation Amount Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Additional noncontingent settlement amount pending Licensing Agreement, Additional Expected Noncontingent Settlement Amount Licensing Agreement, Additional Expected Noncontingent Settlement Amount MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Restructuring Type [Axis] Restructuring Type [Axis] Change in fair value of contingent consideration Increase (decrease) in fair value of contingent consideration Change in fair value of liability Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Revenue Revenues [Abstract] Genevant Genevant [Member] Genevant Enantigen's Selling Shareholders Enantigen's Selling Shareholders [Member] Enantigen's Selling Shareholders Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Financial Instruments [Domain] Financial Instruments [Domain] Unrealized loss on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Segments [Domain] Segments [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Investments in marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Minimum Minimum [Member] Non-cash interest expense Non Cash Interest Expense Related To Sale Of Future Royalties Non Cash Interest Expense Related To Sale Of Future Royalties Amortization of other deferred charges Amortization of Other Deferred Charges Net loss attributable to common shareholders per share Earnings Per Share, Policy [Policy Text Block] Accumulated depreciation of property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Company Selected Measure Name Company Selected Measure Name Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Gross proceeds from sale of royalty interest. before advisory fees Gross Proceeds From Royalty Interest Sold Gross Proceeds From Royalty Interest Sold Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Long Term Marketable Securities Investments in marketable securities, noncurrent [Member] Investments in marketable securities, noncurrent Issuance of common shares pursuant to ESPP Proceeds from Stock Plans Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Stockholders' Equity Note [Abstract] Issued and outstanding: 197,634,118 (December 31, 2025: 192,531,225) Common Stock, Value, Issued Restructuring Plan [Domain] Restructuring Plan [Domain] Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Business Combination [Axis] Business Combination [Axis] Entity Small Business Entity Small Business Costs related to collaboration Other Cost and Expense, Operating Potential milestone payments Potential Milestone Payments Represents the potential milestone payments amount. Document Transition Report Document Transition Report Ownership interest in equity method investment (as a percentage) Equity Method Investment, Ownership Percentage Underlying Securities Award Underlying Securities Amount Number of wholly-owed subsidiaries Wholly Owned Subsidiaries Included in Financial Statements Represents the number of wholly owned subsidiaries included in the reporting of the financial statements. Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Development and regulatory milestones payment per licensed compound series, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per License License Agreement, Maximum Development and Regulatory Milestone Payments Per License Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Royalty guarantees commitments percentage Royalty Guarantees Commitments Percentage Represents the royalty guarantees commitments percentage. Revenue from Contract with Customer [Abstract] Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Name Outstanding Recovery, Individual Name Marketable Securities [Table] Marketable Securities [Table] Gain Contingencies [Table] Loss Contingencies [Table] Additional paid-in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Receivable from Genevant license Accounts and Other Receivables, Net, Current Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from Issuance of Common Stock All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Name Forgone Recovery, Individual Name Total current assets Assets, Current Range [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Other Liabilities Disclosure [Abstract] Weighted average number of common shares Weighted Average Number Of Common Shares [Abstract] Weighted average number of common shares Non-cash royalty revenue Non-cash royalty revenue Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Common Stock, Shares Authorized, Unlimited [Fixed List] Common Stock, Shares Authorized, Unlimited [Fixed List] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current liabilities: Liabilities, Current [Abstract] Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Level 1 Fair Value, Inputs, Level 1 [Member] Foreign exchange (loss) gain Gain (Loss), Foreign Currency Transaction, before Tax Noncontingent settlement amount Noncontingent Settlement Amount Noncontingent Settlement Amount Diluted (in USD per share) Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Title of 12(b) Security Title of 12(b) Security Arbutus Plans Arbutus Plans [Member] Arbutus Plans [Member] Labor hours Service, Other [Member] Net (loss) income per common share Earnings Per Share [Abstract] Restructuring Plan [Axis] Restructuring Plan [Axis] Total other income Nonoperating Income (Expense) Investments, Debt and Equity Securities [Abstract] Investment in Genevant Equity Method Investments and Joint Ventures Disclosure [Text Block] Investments in marketable short-term securities Debt Securities, Available-for-Sale, Current Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Award Timing Disclosures [Line Items] Non-cash interest expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Entitlement of royalties to be received Royalty Interest Sold, Maximum Royalties For Buyer Royalty Interest Sold, Maximum Royalties For Buyer Weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Other early research and development programs expense Other Research and Development Expense Shareholders’ equity Equity [Text Block] Acuitas Therapeutics, Inc. Acuitas Therapeutics Inc. [Member] Acuitas Therapeutics Inc. Net (loss) income Net income Net Income (Loss) Net Income (Loss) Attributable to Parent Expiration Date Trading Arrangement Expiration Date Restructuring Restructuring, Impairment, and Other Activities Disclosure [Text Block] Other liabilities Increase (Decrease) in Other Operating Liabilities Property and equipment, net of accumulated depreciation and impairment of $235 (December 31, 2025: $213) Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Restructuring costs Restructuring Charges Adoption Date Trading Arrangement Adoption Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Entity Current Reporting Status Entity Current Reporting Status Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] (Loss) income from operations Operating Income (Loss) Transaction costs on sale of royalties Transaction Costs Related To Sale Of Future Royalties Transaction Costs Related To Sale Of Future Royalties Deficit Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Non-cash items: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Class of Stock [Axis] Class of Stock [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Contingencies and Commitments [Line Items] Contingencies and Commitments [Line Items] Payables and Accruals [Abstract] Statement [Table] Statement [Table] Number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated Collaborations, contracts and licensing agreements Collaborative Arrangement Disclosure [Text Block] FINANCING ACTIVITIES Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Qilu Pharmaceutical Co, LTD. Qilu Pharmaceutical Co, LTD. [Member] Qilu Pharmaceutical Co, LTD. Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Anti-dilutive common shares excluded from calculation of loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Amendment Flag Amendment Flag Termination Date Trading Arrangement Termination Date Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Revenue recognized as portion of Settlement Agreement Noncontingent Settlement, Revenue Recognized Noncontingent Settlement, Revenue Recognized Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Schedule of activity related to the net liability from inception of the Agreement Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block] Liabilities Related To Sale Of Future Royalties Roll Forward Issuance of common shares upon vesting of RSUs Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Deferred revenue recognized Deferred Income, Revenue Recognized Royalty interest, % interest Royalty interest, Percent interest Royalty interest, % interest Trade accounts payable Accounts Payable, Trade, Current Restructuring and Related Activities [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common shares, shares issued (in shares) Common Stock, Shares, Issued Options granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Unrealized loss on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Proceeds from legal settlements Proceeds from Legal Settlements Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Gain Contingencies [Line Items] Loss Contingencies [Line Items] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Total liabilities Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Operating expenses Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Common Shares Common Stock [Member] Fair Value Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Arbutus Biopharma Corp Arbutus Biopharma Corp [Member] Arbutus Biopharma Corp Professional fee accruals Accrued Professional Fees, Current